Neurocrine Biosciences (NBIX)
Healthcare · Biotechnology
2 members of Congress have disclosed 4 trades in Neurocrine Biosciences (NBIX) since 2023: 1 buy and 3 sales. The most recent was disclosed on Aug 13, 2025.
- Trades disclosed
- 4
- Members trading
- 2
- Buys / sells
- 1 / 3
- Reported value
- $32K–$130K
Keep following the company.
Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.
What else is happening at NBIX
All research →Company filings and public records connected to this stock, ordered by when they became public or were first observed.
NBIX: third_quarter 2026 lobbying report
IRA, prescription drug pricing, payment reform, innovation telehealth, mental health, prescription drug pricing, payment reform federal budget issues
Public: Oct 20, 2026, 3:14 PM EDTOriginal source ↗NBIX: third_quarter 2026 lobbying report
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Public: Oct 20, 2026, 2:20 PM EDTOriginal source ↗NBIX: third_quarter 2026 lobbying report
Issues related to implementation of the Inflation Reduction Act, P.L. 117-169, including potential changes to the structure of and reimbursement for Medicare Part D. H.R. 946 - Orphan Cures Act H.R. 1492 / S. 832 - Ensuring Pathways to Innovative Cures (EPIC) Act Issues related to drug pricing Regulatory and legislative healthcare issues related to pharmaceutical development, approval, reimbursement, and patient access. Issues related to the screening, diagnosis, and treatment of Tardive Dyskinesia. Issues related to telehealth including the Telemental Health Care Access Act of 2023, H.R. 3432
Public: Oct 20, 2026, 12:10 PM EDTOriginal source ↗NBIX: third_quarter 2026 lobbying report
Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impacting pricing and access; issues related to diagnosis and treatment of Tardive Dyskinesia; Diagnosis and treatment of Parkinson's Disease; Issues related to Telehealth; Request appropriations report language to encourage additional support from the Department of Health and Human Services for Tardive Dyskinesia patients. Issues regarding potential changes to structure and reimbursement for Medicare Part D; Regulatory and legislative health care issues impactin
Public: Oct 18, 2026, 1:41 PM EDTOriginal source ↗NBIX: second_quarter 2026 lobbying report
Provide guidance and strategic counsel with regard to regulations and legislation that could impact the biopharmaceutical industry generally such as drug pricing and telehealth policy
Public: Jul 20, 2026, 2:27 PM EDTOriginal source ↗
Who traded NBIX
- Rep. Lisa C. McClain (R-MI-9)1 buy · 1 sale11Aug 13, 2025
- Rep. Michael T. McCaul (R-TX-10)0 buys · 2 sales02Jun 22, 2023
All trades
- Aug 13, 2025$1K–$15K
Rep. Lisa C. McClain (R-MI-9)
Sold (partial) Neurocrine Biosciences NBIX
$1K–$15K · Traded Jun 17, 2025 · disclosed Aug 13, 2025 · Spouse · filed 57 days later
- Aug 13, 2025$1K–$15K
Rep. Lisa C. McClain (R-MI-9)
Bought Neurocrine Biosciences NBIX
$1K–$15K · Traded Jun 11, 2025 · disclosed Aug 13, 2025 · Spouse · filed 63 days later
- Jun 22, 2023$15K–$50K
Rep. Michael T. McCaul (R-TX-10)
Sold Neurocrine Biosciences NBIX
$15K–$50K · Traded May 2, 2023 · disclosed Jun 22, 2023 · filed 51 days later
- Jun 22, 2023$15K–$50K
Rep. Michael T. McCaul (R-TX-10)
Sold Neurocrine Biosciences NBIX
$15K–$50K · Traded May 2, 2023 · disclosed Jun 22, 2023 · Spouse · filed 51 days later
From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.